Clinical Trials Logo

Non-small-cell Lung clinical trials

View clinical trials related to Non-small-cell Lung.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01041235 Completed - Breast Cancer Clinical Trials

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Start date: December 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety profile, including the maximum tolerated dose (MTD), of ATI-1123 a liposomal formulation of docetaxel, in the treatment of cancer patients with advanced solid tumors.

NCT ID: NCT00863746 Completed - Carcinoma Clinical Trials

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

MISSION
Start date: April 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to see if sorafenib plus best supportive care (i.e. in addition to the non-cancer treatments patients would normally receive) is an effective treatment for lung cancer compared to best supportive care alone. The safety and tolerability of the two treatment groups will also be compared. The goal of the study is to test the ability of sorafenib to improve survival compared to best supportive care alone.

NCT ID: NCT00577746 Completed - Non Small Cell Lung Clinical Trials

Clinical Impact of EUS in Staging NSCLC

Start date: June 2006
Phase: N/A
Study type: Observational

The goal of this prospective study is to determine the clinical and economic impact of endoscopic ultrasound (EUS) in staging NSCLC. Aims: 1) Determine the accuracy of EUS in staging NSCLC 2) Measure 5-year survival 3) Measure quality of life in patients that undergo surgery 4) Determine the cost benefit of EUS in staging NSCLC.

NCT ID: NCT00532155 Completed - Carcinoma Clinical Trials

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

VITAL
Start date: September 2007
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC). The secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunogenicity of IV aflibercept in all participants.

NCT ID: NCT00506051 Completed - Lung Cancer Clinical Trials

ZD6474(Vandetanib) + Alimta Combo Study

Start date: July 2005
Phase: Phase 1
Study type: Interventional

The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.

NCT ID: NCT00034879 Completed - Carcinoma Clinical Trials

Iressa Expanded Access Program (EAP)

Start date: August 2000
Phase: Phase 3
Study type: Interventional

A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.